SIGA Technologies, Inc. reported a significant decline in financial performance for the second quarter of 2026, as detailed in its latest 10-Q filing. The company generated total revenues of $41.0 million for the three months ended June 30, 2026, a decrease of 49.5% compared to $81.1 million in the same period of 2025. This decline was primarily driven by a drop in product sales, which fell to $37.9 million from $79.1 million year-over-year. The company’s net income also decreased sharply, totaling $12.5 million for the quarter, down from $35.5 million in the prior year, resulting in a basic income per share of $0.17 compared to $0.50.

For the first half of 2026, SIGA reported total revenues of $47.2 million, down from $88.2 million in the first half of 2025. The decrease in revenue was attributed to lower sales of both oral and intravenous formulations of TPOXX®, particularly under the 19C BARDA Contract with the U.S. Government. The company recognized $25.6 million in IV TPOXX® sales during the first half of 2026, compared to $53.3 million in the same period of 2025. Additionally, the company’s accumulated deficit increased to $77.98 million as of June 30, 2026, from $43.07 million at the end of 2025.

Operationally, SIGA has made strides in international markets, reporting $13.0 million in international sales for the second quarter of 2026, a notable increase from $5.8 million in the same period of 2025. The company also entered into a new exclusive license and distribution agreement with Hikma MENA FZE in March 2026, allowing Hikma to commercialize oral TPOXX® in the Middle East and North Africa. This strategic move is expected to enhance SIGA's market presence in these regions.

The company’s cash and cash equivalents decreased to $117.6 million as of June 30, 2026, down from $155.0 million at the end of 2025. This decline was primarily due to cash used in financing activities, including a special cash dividend payment of approximately $43.3 million. Despite the decrease in cash reserves, SIGA believes its liquidity will be sufficient to meet operational needs for at least the next twelve months. Looking ahead, SIGA is targeting a Supplemental New Drug Application submission for oral TPOXX® for smallpox post-exposure prophylaxis in the first half of 2027, contingent on ongoing trial results.

About SIGA TECHNOLOGIES INC

SIGA Technologies is a pharmaceutical company specializing in antiviral drugs, notably TPOXX (tecovirimat), for smallpox and other orthopoxvirus infections. It supplies government and international markets, focusing on biodefense and pandemic preparedness. The company relies on third-party manufacturers, holds extensive patents, and navigates complex regulatory environments globally to develop and commercialize its antiviral therapies.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov